Novartis, Dana-Farber seek to bar generic leukaemia drug

09-06-2022

Muireann Bolger

Novartis, Dana-Farber seek to bar generic leukaemia drug

rafapress / Shutterstock.com

Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt (midostaurin).


Novartis, Dana-Farber, generics, leukaemia, Rydapt, Hatch-Waxman, patent infringement, US Food and Drug Administration, ANDA, USPTO

LSIPR